Abstract:Traditional tumor models do not tend to accurately simulate tumor growth in vitro or enable personalized treatment and are particularly unable to discover more beneficial targeted drugs. To address this, this study describes the use of three-dimensional (3D) bioprinting technology to construct a 3D model with human hepatocarcinoma SMMC-7721 cells (3DP-7721) by combining gelatin methacrylate (GelMA) and poly(ethylene oxide) (PEO) as two immiscible aqueous phases to form a bioink and innovatively applying fluorescent carbon quantum dots for long-term tracking of cells. The GelMA (10%, mass fraction) and PEO (1.6%, mass fraction) hydrogel with 3:1 volume ratio offered distinct pore-forming characteristics, satisfactory mechanical properties, and biocompatibility for the creation of the 3DP-7721 model. Immunofluorescence analysis and quantitative real-time fluorescence polymerase chain reaction (PCR) were used to evaluate the biological properties of the model. Compared with the two-dimensional culture cell model (2D-7721) and the 3D mixed culture cell model (3DM-7721), 3DP-7721 significantly improved the proliferation of cells and expression of tumor-related proteins and genes. Moreover, we evaluated the differences between the three culture models and the effectiveness of antitumor drugs in the three models and discovered that the efficacy of antitumor drugs varied because of significant differences in resistance proteins and genes between the three models. In addition, the comparison of tumor formation in the three models found that the cells cultured by the 3DP-7721 model had strong tumorigenicity in nude mice. Immunohistochemical evaluation of the levels of biochemical indicators related to the formation of solid tumors showed that the 3DP-7721 model group exhibited pathological characteristics of malignant tumors, the generated solid tumors were similar to actual tumors, and the deterioration was higher. This research therefore acts as a foundation for the application of 3DP-7721 models in drug development research.

Research progress of 3D-bioprinted functional pancreas and in vitro tumor models

The Prospects for Bioprinting Tumor Models: Recent Advances in Their Applications

Grafting of 3D Bioprinting to in Vitro Drug Screening: A Review

Bioprinting of in vitro tumor models for personalized cancer treatment: a review

3D Bioprinting: an Emerging Technology Full of Opportunities and Challenges

Advances in tumor microenvironment: Applications and challenges of 3D bioprinting

Recent advances of three-dimensional bioprinting technology in hepato-pancreato-biliary cancer models

3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling.

3D Bioprinting: A Novel Avenue for Manufacturing Tissues and Organs

3D Bioprinting of Tumor Models and Potential Applications

3D Bioprinting for Next-Generation Personalized Medicine

3D Bioprinting for Pancreas Engineering/Manufacturing

3D‐Bioprinting for Precision Microtissue Engineering: Advances, Applications, and Prospects

3D Bioprinting as a Powerful Technique for Recreating the Tumor Microenvironment

Advancements in Research on Constructing Physiological and Pathological Liver Models and Their Applications Utilizing Bioprinting Technology

3D Bioprinting Tumor Models Mimic the Tumor Microenvironment for Drug Screening

Recent applications of three-dimensional bioprinting in drug discovery and development

Three-dimensional bioprinting of in vitro tumor organoid and organ-on-a-chip models

3D Bioprinting of in Vitro Porous Hepatoma Models: Establishment, Evaluation, and Anticancer Drug Testing

Advanced tumor organoid bioprinting strategy for oncology research

3D Bioprinting for Engineered Tissue Constructs and Patient‐Specific Models: Current Progress and Prospects in Clinical Applications